Nerea Martínez

Nerea Martínez

Auto-generated profile, based on publicly available information

Nerea Martínez

Cancer Genomics, IDIVAL, Santander, Spain

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2014 in Blood
Verified
Journal Article
Closed access
PDF file
JVJosé Pedro Vaqué
José Pedro Vaqué
Gonzalo Gomez-LopezGonzalo Gomez-Lopez
Gonzalo Gomez-Lopez
VMVerónica Monsálvez
Verónica Monsálvez
IVIgnacio Varela
Ignacio Varela
NMNerea Martínez
Nerea Martínez
MSMargarita Sánchez-Beato
Margarita Sánchez-Beato
Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group of primary cutaneous T-cell lymphoproliferative processes, mainly composed of mycosis fungoides and Sézary syndrome, the aggressive forms of which lack an effective treatment. The molecular pathogenesis of CTCL is largely unknown, although neoplastic cells show increased signaling from T-cell receptors (TCRs). DNAs from 11 patients with CTCL, both normal and tumoral, were target-enriched and sequenced by massive parallel sequencing for a selection of 524 TCR–signaling-related genes. Identified variants were validated by capillary sequencing. Multiple mutations were found that affected several signaling pathways, such as TCRs, nuclear factor κB, or Janus kinase/signal transducer and activator of transcription, but PLCG1 was found to be mutated in 3 samples, 2 of which featured a redundant mutation (c.1034T>C, S345F) in exon 11 that affects the PLCx protein catalytic domain. This mutation was further analyzed by quantitative polymerase chain reaction genotyping in a new cohort of 42 patients with CTCL, where it was found in 19% of samples. Immunohistochemical analysis for nuclear factor of activated T cells (NFAT) showed that PLCG1-mutated cases exhibited strong NFAT nuclear immunostaining. Functional studies demonstrated that PLCG1 mutants elicited increased downstream signaling toward NFAT activation, and inhibition of this pathway resulted in reduced CTCL cell proliferation and cell viability. Thus, increased proliferative and survival mechanisms in CTCL may partially depend on the acquisition of somatic mutations in PLCG1 and other genes that are essential for normal T-cell differentiation.

1 September 2005 in Blood
Verified
Journal Article
Closed access
PDF file
ERElena Ruiz-Ballesteros
Elena Ruiz-Ballesteros
MMManuela Mollejo
Manuela Mollejo
ARAntonia Rodriguez
Antonia Rodriguez
FCFrancisca I. Camacho
Francisca I. Camacho
PAPatrocinio Algara
Patrocinio Algara
Miguel PirisMiguel Piris
Miguel Piris
Splenic marginal zone lymphoma (SMZL) is a newly recognized lymphoma type whose precise molecular pathogenesis is still essentially unknown. This hampers differential diagnosis with other small B-cell malignancies. With the aim of characterizing this tumor more comprehensively, and of identifying new diagnostic and prognostic markers, we performed cDNA microarray expression profiling and tissue microarray (TMA) immunohistochemical studies in a relatively large series of 44 SMZLs. The results were related to immunoglobulin heavy chain variable region (IgVH) mutational status and clinical outcome. SMZLs display a largely homogenous signature, implying the existence of a single molecular entity. Of the genes deregulated in SMZLs, special mention may be made of the genes involved in B-cell receptor (BCR) signaling, tumor necrosis factor (TNF) signaling and nuclear factor-κB (NF-κB) activation, such as SYK, BTK, BIRC3, TRAF3, and LTB. Other genes observed were SELL and LPXN, which were highly expressed in spleen, and lymphoma oncogenes, such as ARHH and TCL1. In contrast, the genes CAV1, CAV2, and GNG11 located in 7q31, a commonly deleted area, were down-regulated in the entire series. A comparison with the genes comprising the signature of other small B-cell lymphomas identified 3 genes whose expression distinguishes SMZL, namely ILF1, SENATAXIN, and CD40. Shorter survival was associated with CD38 expression, naive IgVH genes, and the expression of a set of NF-κB pathway genes, including TRAF5, REL, and PKCA. (Blood. 2005;106:1831-1838)

4 May 2005 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
LTLorraine Tracey
Lorraine Tracey
APAlberto Pérez‐Rosado
Alberto Pérez‐Rosado
MAMaria Jesús Artiga
Maria Jesús Artiga
FCFrancisca I Camacho
Francisca I Camacho
ARAntonia Rodríguez
Antonia Rodríguez
Miguel PirisMiguel Piris
Miguel Piris

2 January 2003 in Blood
Verified
Journal Article
Closed access
PDF file
FCFrancisca I. Camacho
Francisca I. Camacho
PAPatrocinio Algara
Patrocinio Algara
ARAntonia Rodrı́guez
Antonia Rodrı́guez
ERElena Ruı́z-Ballesteros
Elena Ruı́z-Ballesteros
MMManuela Mollejo
Manuela Mollejo
Miguel PirisMiguel Piris
Miguel Piris
This study explores whether the presence of somatic mutations or a biased use of IgV H genes were associated with the clinical features in a series of 96 patients with mantle cell lymphoma (MCL). The cases were studied by seminested polymerase chain reaction using primers from the FR1 and JHregions. There was an unexpectedly high frequency of somatic mutations, with 29 of 103 sequences showing more than 2% of mutations. Biased usage of specific V H segments was also found; the most widely used genes in this series wereVH3-21 (10 cases),VH3-23 (9 cases),VH4-34 (11 cases), andVH4-59 (9 cases).V H mutation frequency, taking into account different thresholds, did not distinguish different overall survival probabilities. Nevertheless, a more frequent use ofVH3-21 or VH4-59 (8 of 18) was observed in the group of long-term survivors (18 cases > 5 years; P < .01). None of these long-term survivors presented the VH3-23 gene rearrangement. As in other lymphoproliferative disorders, the expression of CD38 or p53 or both was associated with a poorer survival probability. This nonrandom usage of IgVH segments suggests that specific antigens may play a pathogenically relevant role in the genesis or progression of subsets of MCL cases and may help in distinguishing a significant group of MCL long-term survivors.

3 December 2013 in Leukemia
Verified
Journal Article
Closed access
NMN Martínez
N Martínez
CAC Almaraz
C Almaraz
JVJosé Pedro Vaqué
José Pedro Vaqué
IVI Varela
I Varela
SDS Derdak
S Derdak
Miguel PirisMiguel Piris
Miguel Piris

1 May 2015 in American Journal of Surgical Pathology
Verified
Journal Article
Closed access
AMAzahara Martinez-Lopez
Azahara Martinez-Lopez
SCSoraya Curiel-Olmo
Soraya Curiel-Olmo
MMManuela Mollejo
Manuela Mollejo
LCLaura Cereceda
Laura Cereceda
NMNerea Martinez
Nerea Martinez
Miguel PirisMiguel Piris
Miguel Piris
MYD88 L265P is a somatic mutation that has been identified in about 90% of Waldenström macroglobulinemia/lymphoplasmacytic lymphomas (LPLs). It has also been detected in a subset of marginal zone lymphoma (MZL) cases, but the frequency and clinical and histologic features of these mutated MZL cases has only been partially characterized. We have developed a customized TaqMan allele-specific polymerase chain reaction for sensitive detection of this mutation in paraffin-embedded tissue. We analyzed samples from 19 patients with LPL, 88 patients with splenic marginal zone lymphoma (SMZL), 8 patients with nodal marginal zone lymphoma (NMZL), 21 patients with extranodal mucosa-associated lymphoid tissue (MALT), and 2 patients with B-cell lymphoma not otherwise specified. By integrating mutational, histologic, and clinical data, 5 cases were reclassified as LPL. After reclassification, MYD88 L265P was detected in 13/86 (15%) SMZL and in 19/24 LPL (79%) cases. The mutation was absent from NMZL and MALT cases. A strong correlation was found between the presence of an IgM monoclonal paraproteinemia and the MYD88 L265P mutation (P<0.0001). SMZL cases positive for MYD88 L265P were also associated with monoclonal IgM paraproteinemia (4/13 cases; P<0.0283), although with less serum paraproteinemia. They also had a higher frequency of plasmacytic differentiation (9/13) but with no correlation between the presence of mutation and of light chain-restricted plasma cells in tissue. Demonstration of the MYD88 L265 mutation is a valuable tool for the diagnosis of LPL, although some SMZL cases carrying the mutation do not fulfill the diagnostic criteria for LPL.